Identification

Name
Nylidrin
Accession Number
DB06152
Type
Small Molecule
Groups
Approved
Description

Nylidrin, also known as buphenine belongs to the category of drugs called vasodilators, which relax blood vessels and increase blood flow. Nylidrin is a peripheral vasodilator. Some studies show the evidence of improving cognitive impairment in selected individuals, such as geriatric patients with mild to moderate symptoms of cognitive, emotional and physical impairment [4].

Nylidrin is utilized to treat several disorders that may benefit from increased blood flow (for example, certain mental disorders, blood vessel disease due to diabetes, frostbite, night leg cramps, and certain types of ulcers). This medication works by dilating (widening) blood vessels to help increase blood flow (improving circulation) throughout the body, including the extremities and central nervous system. This effect may help to improve memory/judgment, improve walking ability, and support the healing of frostbite/ulcers [6].

FDA has considered nylidrin as "lacking substantial evidence of effectiveness" in cerebral ischemia, cerebral arteriosclerosis, and other cerebral circulatory insufficiencies. Therefore, the FDA has withdrawn nylidrin from the U.S. market [9].

Structure
Thumb
Synonyms
  • Bufenina
  • Buphenin
  • Buphenine
  • Bupheninum
External IDs
CS 6712 / SKF 1700-A
Product Ingredients
IngredientUNIICASInChI Key
Nylidrin hydrochlorideEC69E3PW7E849-55-8CLJHABUMMDMAFA-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Arlidin Forte Tab 12mgTablet12 mgOralAventis Pharma Ltd.1974-12-312003-07-22Canada
Arlidin Tablets 6mgTablet6 mgOralErfa Canada 2012 Inc1955-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PMS-nylidrin Tab 6mgTablet6 mgOralPharmascience Inc1983-12-312016-10-28Canada
International/Other Brands
Arbid / Arlidin
Categories
UNII
695DKH33EI
CAS number
447-41-6
Weight
Average: 299.414
Monoisotopic: 299.188529049
Chemical Formula
C19H25NO2
InChI Key
PTGXAUBQBSGPKF-UHFFFAOYSA-N
InChI
InChI=1S/C19H25NO2/c1-14(8-9-16-6-4-3-5-7-16)20-15(2)19(22)17-10-12-18(21)13-11-17/h3-7,10-15,19-22H,8-9H2,1-2H3
IUPAC Name
4-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]propyl}phenol
SMILES
CC(CCC1=CC=CC=C1)NC(C)C(O)C1=CC=C(O)C=C1

Pharmacology

Indication

Nylidrin is mainly indicated in conditions like arteriosclerosis, cerebrovascular disease, peripheral vascular disease, Raynaud's disease, thrombo-angitis obliterans, and thrombophlebitis [8]. It may sometimes be used in the treatment of peripheral vascular disorders in addition premature labor (however, the drug is not approved for premature labor)[2].

Structured Indications
Not Available
Pharmacodynamics

Nylidrin hydrochloride acts mainly by beta-receptor stimulation [1], [15]. Beta stimulation with nylidrin has been studied and confirmed in a variety of isolated tissues from rabbits, guinea pigs, as well as dogs. This drug has been shown to dilate arterioles in skeletal muscle and to increase cardiac output in the anesthetized dog and cat as well as the unanesthetized man. An increase in cerebral blood flow and a decrease in vascular resistance has also been reported. The result of this combination of mechanisms is an improved blood supply to ischemic tissues, with minimal change in blood pressure (generally) [16].

Nylidrin causes peripheral vasodilation, a positive inotropic effect, and an increased volume of gastric acid. [2], [4]. According to one study, there are two primary effects of this agent following the intra‐arterial route of administration: one, to decrease total peripheral resistance; and two, a direct effect on the heart tissue to increase cardiac output [15]. It also acts directly on the arteries and arterioles of the skeletal muscles. Additionally, it suppresses uterine contractility thereby preventing or halting premature labor [11].

Mechanism of action

This drug is classified as a beta receptor agonist [7].The β2-adrenergic receptor belongs to the widely expressed 7-transmembrane receptors superfamily, which signals through heterotrimeric G-proteins. They are frequently referred to as G-protein-coupled receptors because they accomplish signal transduction to the interior of the cell by interactions with guanine nucleotide regulatory binding proteins. The receptor-coupled G-proteins work as “molecular switches” which alternate from an inactive guanosine-diphosphate to an active guanosine-triphosphate (GTP) state, which then act to modulate all downstream cell processes. Signaling by various hormones and neurotransmitters, as well as photons and odors, follows the same general pathway, (i.e., by binding of an extracellular ligand to the receptor, which then interacts with the membrane-bound G-protein). This complex, often referred to as the ternary complex, then acts through the activated G-protein to regulate an effector, such as adenylyl cyclase, phospholipase C, or ion channels [14].

The main effects of Nylidrin may be divided into 3 categories:

Blood vessels

Vascular smooth muscle has β2-adrenoceptors that have a high binding affinity for circulating epinephrine and a lower affinity to norepinephrine released by sympathetic adrenergic nerves [16]. When nylidrin binds to the beta-adrenergic receptors, it prevents the binding of epinephrine, leading to decreased blood vessel contractility as epinephrine is unable to bind [18].

Heart:

Increased intracellular cAMP by beta-2-agonists inhibits myosin light chain kinase, leading to relaxation These receptors, like the receptors in the heart, are coupled to a Gs-protein, which acts stimulate the formation of cAMP. Although increased cAMP increases cardiac myocyte contraction, in vascular smooth muscle, an increase in cAMP causes smooth muscle relaxation. The reason for this is the fact that cAMP inhibits myosin light chain kinase that is responsible for phosphorylating smooth muscle myosin. Increases in intracellular cAMP caused by β2-agonists inhibit myosin light chain kinase thereby producing less contractile force (i.e., promoting relaxation) [16].

Other tissues

Activation of β2-adrenoceptors in the lungs causes bronchodilation. β2-adrenoceptor activation leads to hepatic glycogenolysis and the pancreatic secretion of glucagon, increasing plasma glucose concentrations. β1-adrenoceptor stimulation in the kidneys promotes the release of renin, stimulating the production of angiotensin II and the subsequent release of aldosterone by the adrenal cortex [16].

TargetActionsOrganism
UVoltage-dependent T-type calcium channel subunit alpha-1I
antagonist
agonist
Human
AInterferon alpha/beta receptor 2
agonist
Human
Absorption

Readily absorbed from the gastrointestinal tract [4].

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

Duration of action is 10h [9].

Clearance
Not Available
Toxicity

Adverse effects of oral sympathomimetics, such as Nylidrin, are common. The most frequent effects are hypertension, palpitations, nausea, anxiety, mydriasis, and restlessness/agitation [9].

Large overdoses and severe toxicity may lead to seizures, hallucinations, agitated delirium, and tachydysrhythmias including supraventricular tachycardia and ventricular tachycardia. Vasospasm can lead to myocardial ischemia focal cerebrovascular deficits. Severe hypertension may also result in intracranial hemorrhage or renal insufficiency. Reflex bradycardia because of significant hypertension is possible. Prolonged agitation can lead to rhabdomyolysis and hyperthermia [9].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Nylidrin.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Nylidrin.Vet Approved
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Nylidrin.Approved, Investigational
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Nylidrin.Approved, Investigational
AmobarbitalThe metabolism of Nylidrin can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Nylidrin.Approved, Investigational
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Nylidrin.Approved, Illicit, Investigational
Amphotericin BThe therapeutic efficacy of Amphotericin B can be increased when used in combination with Nylidrin.Approved, Investigational
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Nylidrin.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Nylidrin.Investigational
ArtemetherThe therapeutic efficacy of Artemether can be increased when used in combination with Nylidrin.Approved
AtomoxetineAtomoxetine may increase the hypertensive activities of Nylidrin.Approved
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Nylidrin.Experimental
BarbexacloneThe metabolism of Nylidrin can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Nylidrin can be increased when combined with Barbital.Illicit
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Nylidrin.Approved, Investigational
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Nylidrin.Approved, Illicit
Benzylpenicilloyl PolylysineNylidrin may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Nylidrin.Approved, Investigational
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Nylidrin.Experimental
BromocriptineBromocriptine may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved, Investigational
BucindololThe risk or severity of adverse effects can be increased when Nylidrin is combined with Bucindolol.Investigational
BunazosinBunazosin may decrease the vasoconstricting activities of Nylidrin.Investigational
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Nylidrin.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Nylidrin.Approved
CabergolineCabergoline may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved
Calcium AcetateThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium Phosphate.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Nylidrin.Withdrawn
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Nylidrin.Experimental
CarvedilolCarvedilol may decrease the vasoconstricting activities of Nylidrin.Approved, Investigational
CaseinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Nylidrin.Approved
CeliprololThe risk or severity of adverse effects can be increased when Celiprolol is combined with Nylidrin.Approved, Investigational
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Nylidrin.Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Nylidrin.Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Nylidrin.Illicit, Withdrawn
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Nylidrin.Approved, Investigational
CimetidineThe serum concentration of Nylidrin can be increased when it is combined with Cimetidine.Approved, Investigational
ClenbuterolThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Nylidrin.Approved, Investigational, Vet Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nylidrin.Approved
ClotrimazoleThe therapeutic efficacy of Clotrimazole can be increased when used in combination with Nylidrin.Approved, Vet Approved
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Nylidrin.Investigational
CyclosporineThe therapeutic efficacy of Cyclosporine can be increased when used in combination with Nylidrin.Approved, Investigational, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Nylidrin.Approved, Investigational
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Nylidrin.Vet Approved
DihydroergotamineDihydroergotamine may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved, Investigational
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Nylidrin.Approved
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Nylidrin.Approved
DoxazosinDoxazosin may decrease the vasoconstricting activities of Nylidrin.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Doxofylline.Approved, Investigational
DronabinolDronabinol may increase the tachycardic activities of Nylidrin.Approved, Illicit
DuloxetineDuloxetine may increase the tachycardic activities of Nylidrin.Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Nylidrin.Approved
EfavirenzThe serum concentration of Nylidrin can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Nylidrin.Approved
EpanololThe risk or severity of adverse effects can be increased when Nylidrin is combined with Epanolol.Experimental
EphedrineThe risk or severity of adverse effects can be increased when Ephedrine is combined with Nylidrin.Approved
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Nylidrin.Approved, Vet Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved
ErgonovineErgonovine may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved
ErgotamineErgotamine may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved
EtilefrineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Etilefrine.Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Nylidrin.Approved, Investigational
FenozoloneThe risk or severity of adverse effects can be increased when Nylidrin is combined with Fenozolone.Experimental
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Nylidrin.Experimental
FluconazoleThe therapeutic efficacy of Fluconazole can be increased when used in combination with Nylidrin.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Nylidrin.Approved, Investigational
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Nylidrin.Experimental
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Nylidrin.Experimental
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Nylidrin.Approved, Investigational, Vet Approved
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Nylidrin.Experimental
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Nylidrin.Approved, Withdrawn
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Nylidrin.Approved, Investigational
HexobarbitalThe metabolism of Nylidrin can be increased when combined with Hexobarbital.Approved
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Hydroxyamphetamine.Approved
IndoraminIndoramin may decrease the vasoconstricting activities of Nylidrin.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Nylidrin.Approved, Investigational
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Nylidrin.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Nylidrin.Approved, Investigational
IsoxsuprineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Isoxsuprine.Approved, Withdrawn
ItraconazoleThe therapeutic efficacy of Itraconazole can be increased when used in combination with Nylidrin.Approved, Investigational
KetoconazoleThe therapeutic efficacy of Ketoconazole can be increased when used in combination with Nylidrin.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Nylidrin.Approved
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Nylidrin.Approved, Investigational
LinezolidLinezolid may increase the hypertensive activities of Nylidrin.Approved, Investigational
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Nylidrin is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Nylidrin is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Nylidrin is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Nylidrin is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
MefenorexThe risk or severity of adverse effects can be increased when Nylidrin is combined with Mefenorex.Experimental
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Nylidrin.Experimental
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Nylidrin.Approved
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Nylidrin.Approved, Investigational
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Nylidrin.Approved, Illicit
MethohexitalThe metabolism of Nylidrin can be increased when combined with Methohexital.Approved
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Nylidrin.Approved, Investigational
MethylergometrineMethylergometrine may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved
MethylphenobarbitalThe metabolism of Nylidrin can be increased when combined with Methylphenobarbital.Approved
MevastatinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Nylidrin.Experimental
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Nylidrin.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Nylidrin.Approved, Investigational, Vet Approved
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Nylidrin.Approved
MilnacipranMilnacipran may increase the tachycardic activities of Nylidrin.Approved, Investigational
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Nylidrin.Approved, Investigational
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Nylidrin.Vet Approved
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Nylidrin.Experimental
NabiloneNabilone may increase the tachycardic activities of Nylidrin.Approved, Investigational
NafcillinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Nylidrin.Approved
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Nylidrin.Approved
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Nylidrin.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Nylidrin.Investigational
NitroprussideNylidrin may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Nylidrin.Approved
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Nylidrin.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Nylidrin.Approved, Vet Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Nylidrin.Experimental
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Nylidrin.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Nylidrin.Approved
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Nylidrin.Approved, Investigational
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Nylidrin.Investigational
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Nylidrin.Approved, Investigational
PentobarbitalThe metabolism of Nylidrin can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Nylidrin.Approved, Illicit
PhenobarbitalThe metabolism of Nylidrin can be increased when combined with Phenobarbital.Approved, Investigational
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Nylidrin.Approved, Illicit
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Nylidrin.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Nylidrin.Approved, Vet Approved, Withdrawn
PosaconazoleThe therapeutic efficacy of Posaconazole can be increased when used in combination with Nylidrin.Approved, Investigational, Vet Approved
PrazosinPrazosin may decrease the vasoconstricting activities of Nylidrin.Approved
PrenalterolThe risk or severity of adverse effects can be increased when Nylidrin is combined with Prenalterol.Experimental
PrimidoneThe metabolism of Nylidrin can be increased when combined with Primidone.Approved, Vet Approved
ProcaterolThe risk or severity of adverse effects can be increased when Procaterol is combined with Nylidrin.Approved, Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Pseudoephedrine.Approved
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Nylidrin.Experimental
RacepinephrineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Racepinephrine.Approved
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Nylidrin.Experimental
RifabutinThe risk or severity of hypotension can be increased when Rifabutin is combined with Nylidrin.Approved, Investigational
RifampicinThe risk or severity of hypotension can be increased when Rifampicin is combined with Nylidrin.Approved
RifapentineThe risk or severity of hypotension can be increased when Rifapentine is combined with Nylidrin.Approved, Investigational
RifaximinThe risk or severity of hypotension can be increased when Rifaximin is combined with Nylidrin.Approved, Investigational
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Nylidrin.Approved, Investigational
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Nylidrin.Experimental
Salicylic acidThe therapeutic efficacy of Salicylic acid can be increased when used in combination with Nylidrin.Approved, Investigational, Vet Approved
SecobarbitalThe metabolism of Nylidrin can be increased when combined with Secobarbital.Approved, Vet Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Nylidrin.Approved, Investigational
SilodosinSilodosin may decrease the vasoconstricting activities of Nylidrin.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Nylidrin.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Nylidrin.Approved, Investigational
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Nylidrin.Approved
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Nylidrin.Approved
SynephrineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Synephrine.Experimental
TamsulosinTamsulosin may decrease the vasoconstricting activities of Nylidrin.Approved, Investigational
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Nylidrin.Approved, Investigational
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Nylidrin.Approved
TerazosinTerazosin may decrease the vasoconstricting activities of Nylidrin.Approved
TerbinafineThe therapeutic efficacy of Terbinafine can be increased when used in combination with Nylidrin.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Nylidrin.Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Nylidrin.Approved
TetryzolineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Tetryzoline.Approved
ThiamylalThe metabolism of Nylidrin can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Nylidrin can be increased when combined with Thiopental.Approved, Vet Approved
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Nylidrin.Approved
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Nylidrin.Approved
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Nylidrin.Experimental
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Nylidrin.Approved, Investigational, Vet Approved
TramazolineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Tramazoline.Investigational
TretoquinolThe risk or severity of adverse effects can be increased when Nylidrin is combined with Tretoquinol.Experimental
TrimazosinTrimazosin may decrease the vasoconstricting activities of Nylidrin.Experimental
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Nylidrin.Approved, Investigational
TyramineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Tyramine.Investigational, Nutraceutical
UrapidilUrapidil may decrease the vasoconstricting activities of Nylidrin.Investigational
VenlafaxineVenlafaxine may increase the tachycardic activities of Nylidrin.Approved
VoriconazoleThe therapeutic efficacy of Voriconazole can be increased when used in combination with Nylidrin.Approved, Investigational
Food Interactions
  • Take without regard to meals.

References

General References
  1. Niemeyer G, Cottier D, Resch H: Effects of buphenine (nylidrin) on the perfused mammalian eye. Graefes Arch Clin Exp Ophthalmol. 1987;225(1):33-8. [PubMed:2883089]
  2. Castren O, Gummerus M, Saarikoski S: Treatment of imminent premature labour. Acta Obstet Gynecol Scand. 1975;54(2):95-100. [PubMed:1094787]
  3. Walter U, Waldmann R, Nieberding M: Intracellular mechanism of action of vasodilators. Eur Heart J. 1988 Jun;9 Suppl H:1-6. [PubMed:3049092]
  4. PubChem, Nylidrin [Link]
  5. Nylidrin (Oral) [Link]
  6. Nylidrin - Oral [Link]
  7. Nylidrin [Link]
  8. Drug monograph [Link]
  9. ToxNet Nylidrin [Link]
  10. Central cardiovascular effects of nylidrin (buphenine) [Link]
  11. Buphenine, MIMS [Link]
  12. Central cardiovascular effects of nylidrin (buphenine). [Link]
  13. Nylidrin [Link]
  14. Beta-Adrenergic Agonists [Link]
  15. Local and systemic hemodynamic effects of nylidrin [Link]
  16. Nylidrin Hydrochloride [Link]
  17. Specific blockade of spasmogens by β‐receptor stimulation with nylidrin and isoprenaline [Link]
  18. NyIidrin HCL: A BETA-SYMPATHETIC STIMULANT IN THE MANAGEMENT OF HAEMORRHAGIC SHOCK [Link]
External Links
PubChem Compound
4567
PubChem Substance
347827757
ChemSpider
4407
ChEBI
91656
ChEMBL
CHEMBL114655
Wikipedia
Nylidrin
ATC Codes
G02CA02 — BuphenineC04AA02 — Buphenine
AHFS Codes
  • 24:12.92 — Miscellaneous Vasodilatating Agents
MSDS
Download (107 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral12 mg
TabletOral6 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)217MSDS
Predicted Properties
PropertyValueSource
Water Solubility0.0204 mg/mLALOGPS
logP2.73ALOGPS
logP3.05ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)9.25ChemAxon
pKa (Strongest Basic)10.11ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area52.49 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity90.06 m3·mol-1ChemAxon
Polarizability34.56 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpropanes. These are organic compounds containing a phenylpropane moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylpropanes
Direct Parent
Phenylpropanes
Alternative Parents
Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives / Aromatic alcohols
Substituents
Phenylpropane / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Aralkylamine / 1,2-aminoalcohol / Secondary alcohol / Secondary aliphatic amine / Secondary amine / Hydrocarbon derivative / Organopnictogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
Agonist
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1I
Uniprot ID
Q9P0X4
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1I
Molecular Weight
245100.8 Da
References
  1. Central cardiovascular effects of nylidrin (buphenine). [Link]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Type i interferon receptor activity
Specific Function
Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are direc...
Gene Name
IFNAR2
Uniprot ID
P48551
Uniprot Name
Interferon alpha/beta receptor 2
Molecular Weight
57758.24 Da
References
  1. ToxNet Nylidrin [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
O-methyltransferase activity
Specific Function
Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOP...
Gene Name
COMT
Uniprot ID
P21964
Uniprot Name
Catechol O-methyltransferase
Molecular Weight
30036.77 Da
References
  1. Kurki T, Schultz E, Linden IB, Ylikorkala O: Catechol-O-methyltransferase activity in red blood cells in threatened preterm labor; effect of indomethacin and nylidrin. Acta Obstet Gynecol Scand. 1991;70(3):187-91. [PubMed:1927294]

Drug created on January 20, 2008 19:19 / Updated on May 21, 2018 17:37